Autopsy report · NCT02623465

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

“Change in clinical strategy”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Diabetes Mellitus, Type 2

Interventions

Insulin Lispro

Participants

0

Trials that died the same way

• Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
  “Change in the clinical development plan” (74% match in meaning)
• Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
  “the change of clinical development plan” (70% match in meaning)
• Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
  “Change in clinical plan and drug supply” (68% match in meaning)
• A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
  “The sponsor adjusts the clinical development strategy.” (67% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.